Insider trade

Director sold ~$22.1M of ROIV shares in the open market

Traded Dec 31, 2025 · Filed Jan 1, 2026

Why it stands out

A board member of Roivant Sciences sold $22.1M of Roivant Sciences shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$1M+

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$22,122,381

Shares × reported transaction price

Timing vs results

51 days after results of Nov 10, 2025, 37 days before results of Feb 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.2%	+1.6%	−1.4%
30 days	+0.1%	+1.8%	−1.7%
90 days	+29.2%	−4.0%	+33.2%
180 days	+59.7%	+9.2%	+50.6%

Past results only. Not a forecast.

All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.74, inclusive.